Denali Therapeutics Inc. Stock Sao Paulo
Stocks
D2NL34
BRD2NLBDR008
Biotechnology & Medical Research
|
Market Closed -
Sao Paulo
14:04:39 2026-07-13 EDT
|
5-day change | 1st Jan Change | ||
| 27.06 BRL | -1.31% |
|
-.--% | +25.57% |
| 08-25 | B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating | MT |
| 08-24 | FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome | RE |
| Market Cap | 3.72B 19.16B 3.21B 3.02B 2.75B 5.17B 353B 5.2B 35.77B 13.89B 179B 13.96B 13.66B 596B | P/E 2026 * |
-10x | P/E 2027 * | -10.1x |
|---|---|---|---|---|---|
| Enterprise Value | 3.01B 15.51B 2.6B 2.44B 2.23B 4.18B 286B 4.21B 28.95B 11.24B 145B 11.3B 11.06B 482B | EV / Sales 2026 * |
59.9x | EV / Sales 2027 * | 23.4x |
| Free-Float |
90.03% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Denali Therapeutics Inc.
| 1 day | -1.31% | ||
| 3 months | +31.61% | ||
| 6 months | +21.95% | ||
| Current year | +25.57% |
| Current year | 19.44 |  | 27.42 |
| 1 year | 13.5 | | 27.42 |
| 3 years | 13.48 | | 36.2 |
| 5 years | 13.48 | | 40.04 |
| 10 years | 13.48 | | 40.04 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alexander Schuth
DFI | Director of Finance/CFO | 52 | 2022-04-30 |
Ryan Watts
CEO | Chief Executive Officer | 50 | 2015-07-31 |
Peter Chin
CTO | Chief Tech/Sci/R&D Officer | 58 | 2025-11-05 |
| Director | Title | Age | Since |
|---|---|---|---|
Ryan Watts
BRD | Director/Board Member | 50 | 2015-02-28 |
Jay Flatley
BRD | Director/Board Member | 73 | 2015-03-31 |
David Schenkein
BRD | Director/Board Member | 68 | 2015-03-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.31% | -.--% | - | - | 3.8B | |
| -0.25% | -0.92% | +49.47% | +89.45% | 68.13B | |
| +1.21% | +2.55% | +46.72% | +90.66% | 63.6B | |
| +1.31% | +1.81% | +49.04% | +12.07% | 25.57B | |
| -0.25% | -1.99% | -10.72% | +455.09% | 26.6B | |
| +0.33% | -9.64% | +1.95% | -15.70% | 25.52B | |
| -6.09% | -11.19% | +224.80% | +351.08% | 18.23B | |
| +1.18% | +1.66% | +35.20% | -18.67% | 19.69B | |
| -1.49% | -6.35% | +7.84% | +540.26% | 15.16B | |
| +4.12% | +4.29% | +52.03% | +154.09% | 13.54B | |
| Average | -0.12% | -3.84% | +50.70% | +184.26% | 30.67B | |
| Weighted average by Cap. | +0.13% | -2.87% | +47.00% | +145.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 50.26M 259M 43.35M 40.79M 37.18M 69.83M 4.77B 70.32M 483M 188M 2.43B 189M 185M 8.05B | 127M 654M 109M 103M 93.88M 176M 12.05B 178M 1.22B 474M 6.12B 476M 466M 20.32B |
| Net income | -454M -2.34B -392M -369M -336M -631M -43.15B -636M -4.37B -1.7B -21.93B -1.71B -1.67B -72.78B | -453M -2.33B -390M -367M -335M -629M -42.96B -633M -4.35B -1.69B -21.84B -1.7B -1.66B -72.48B |
| Net Debt | -708M -3.65B -611M -575M -524M -984M -67.26B -991M -6.81B -2.65B -34.19B -2.66B -2.6B -113B | -749M -3.86B -646M -608M -554M -1.04B -71.08B -1.05B -7.2B -2.8B -36.14B -2.81B -2.75B -120B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DNLI Stock
- D2NL34 Stock
Select your edition
All financial news and data tailored to specific country editions
